Please assess the completion status of the following clinical trial:

Trial Title: ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult (≥ 18 years old) men or women, hospitalized or not hospitalized, diagnosed for SARS-CoV-2 infection by PCR, with at least one associated risk factor. Considered risk factors are:~   * Age ≥ 65 years~  * Obesity defined as BMI ≥ 30~  * Recent history of uncontrolled High Blood Pressure (SBP \> 150 mm Hg DBP \>100 mm Hg) according to investigator~  * Treated diabetes (type I or II)~  * History of ischemic cardiovascular disease~2. Symptomatic patients at enrollment. Symptoms are defined as fever (body temperature ≥ 37.8 C oral/tympanic, or ≥ 38.2 C rectal) for more than 24 hours associated either with headache, sore throat, dry cough, fatigue, chest pain or choking sensation (with no associated respiratory distress), myalgia, anosmia or ageusia.~3. Patients with pulse oximetry arterial saturation ≥ 92 % on room air at enrolment.~4. Patients with the following hematological and biochemical laboratory parameters obtained within 7 days prior to Day 0:~   * Hemoglobin above 9.0 g / dL~  * Absolute Neutrophil Count ≥ 1000 / mm3~  * Platelets ≥ 100 000 mm3;~  * Creatinine clearance ≥ 50 mL / min by the Cockcroft Gault formula~  * Total serum bilirubin \< 2 x ULN~  * Alkaline phosphatase \< 2 x ULN, AST (SGOT) and ALT (SGPT) \< 3 x ULN;~Exclusion Criteria:~1. Patients with moderate or severe acute respiratory failure or requiring noninvasive ventilation or oxygen or with SpO2 \< 92% or tachypnea (respiratory rate ≥ 30 breaths/min).~2. Patients treated with immunosuppressors and/or immunomodulators.~3. Engrafted patients (organ and/or hematopoietic stem cells).~4. Patients with uncontrolled auto-immune disease.~5. Patients with known or suspected active (i.e. not controlled) bacterial, viral (excluding COVID-19) or fungal infections.~6. Patients with preexisting, severe and not controlled organ failure.~7. History or active malignancy requiring chemotherapy or radiation therapy (excluding 2 years disease free survivor patients).~8. Pregnant or breast-feeding women.~9. Illicit drug or alcohol abuse or dependence that may compromise the patient's safety or adherence to the study protocol.~10. Use of any investigational or non-registered product within 3 months or within 5 half-lives preceding baseline, whichever is longer.~11. Hypersensitivity to ABX464 and/or its excipients.~12. Any condition, which in the opinion of the investigator, could compromise the patient's safety or adherence to the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABX464 (Type: EXPERIMENTAL): ABX464 - Capsules + Standard of Care (SOC)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo - Capsules + Standard of Care (SOC)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility